| John Patrick Sullivan, MD | |
|
850 W Baraga Ave, Marquette, MI 49855-4550 | |
| (906) 449-3000 | |
| Not Available |
| Full Name | John Patrick Sullivan |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 24 Years |
| Location | 850 W Baraga Ave, Marquette, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952368557 | NPI | - | NPPES |
| 64098940 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 39464 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital - The Heart Center | Roslyn, NY | Hospital |
| Owensboro Health Regional Hospital | Owensboro, KY | Hospital |
| Christus St Frances Cabrini Hospital | Alexandria, LA | Hospital |
| Rapides Regional Medical Center | Alexandria, LA | Hospital |
| Good Samaritan Hospital Medical Center | West islip, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eagle Partners Pllc | 9032205752 | 92 |
| Imaging Associates Of Michigan Pllc | 9537434386 | 66 |
| Imaging Associates Of New Mexico Llc | 4981970233 | 97 |
| Coastal Radiology Associates Pllc | 8224002696 | 88 |
| Columbus Radiology Corp | 6507754983 | 271 |
| Eagle Partners Pllc | 9032205752 | 92 |
| Empire State Radiology P C | 4385075241 | 175 |
| Greensboro Radiology Pa | 8729074901 | 207 |
| Imaging Associates Of Indiana Pc | 1254503345 | 202 |
| Imaging Associates Of Michigan Pllc | 9537434386 | 66 |
| Imaging Associates Of New Mexico Llc | 4981970233 | 97 |
| Louisville Radiology Imaging Consultants Pllc | 2264436120 | 54 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
| Northside Radiology Associates Llc | 4486555398 | 213 |
| Radiology Associates Of Southwest Louisiana | 0941243562 | 94 |
| Singleton Associates Pa | 6305731118 | 691 |
| Specialists In Medical Imaging Sc | 2163733544 | 201 |
| Singleton Associates Pa | 6305731118 | 691 |
| Empire State Radiology P C | 4385075241 | 175 |
| Hurley Medical Center | 2961308481 | 264 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
| Northside Radiology Associates Llc | 4486555398 | 213 |
| Blessing Hospital | 3072422534 | 345 |
| Blessing Hospital | 3072422534 | 345 |
| Murfreesboro Radiology And Nuclear Medicine Consultants Pllc | 7719964063 | 62 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Columbus Diagnostic Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316108624 PECOS PAC ID: 3375455884 Enrollment ID: O20040429001218 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Georgia Radiology Imaging Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831461771 PECOS PAC ID: 5698930774 Enrollment ID: O20120625000184 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Louisville Radiology Imaging Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639115447 PECOS PAC ID: 2264436120 Enrollment ID: O20130321000039 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Singleton Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538107875 PECOS PAC ID: 6305731118 Enrollment ID: O20150429000171 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Eagle Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548450976 PECOS PAC ID: 9032205752 Enrollment ID: O20170921001749 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Coastal Radiology Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144270307 PECOS PAC ID: 8224002696 Enrollment ID: O20171030003199 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Imaging Associates Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164943007 PECOS PAC ID: 9537434386 Enrollment ID: O20171031001599 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Entity Name | Imaging Associates Of New Mexico Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629592464 PECOS PAC ID: 4981970233 Enrollment ID: O20171228002395 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Patrick Sullivan, MD 1218 S Broadway, Suite 310, Lexington, KY 40504-2759 Ph: (859) 219-0542 | John Patrick Sullivan, MD 850 W Baraga Ave, Marquette, MI 49855-4550 Ph: (906) 449-3000 |
News Archive
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Harnessing the well-documented healing properties of Turmeric with superior absorption, the world's first Turmeric Oral Spray has been honoured at one of the industry's most prestigious award ceremonies.
The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
› Verified 9 days ago
Dr. Nidhi Azad Gupta, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 850 W Baraga Ave, Marquette, MI 49855 Phone: 906-449-3000 | |
Michael V. Ouimette, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 580 W College Ave, Marquette, MI 49855 Phone: 906-225-7808 | |
Dr. Henry Kai Lee, M. D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 580 W College Ave, Radiation Oncology Depart., Marquette General Hosp., Marquette, MI 49855 Phone: 906-225-3102 | |
Christopher J Mehall, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 580 W College Ave, Marquette, MI 49855 Phone: 906-225-7808 | |
Dr. Hasnain Haider-shah, M.D., C.M. Radiology Medicare: Not Enrolled in Medicare Practice Location: 580 W College Ave, Marquette, MI 49855 Phone: 906-225-7808 | |
Paul O Thieme Jr., DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 420 W Magnetic Street, Marquette, MI 49855 Phone: 906-228-9440 Fax: 906-225-3772 | |
Dr. Christina Arnoldus, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 580 W College Ave, Marquette, MI 49855 Phone: 906-225-4845 |